Skip to Main Content

Paper Details

Trends in Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy Among Medicare Part B Fee-for-Service Beneficiaries.
JAMA Ophthalmol
13
2022
DME, Diabetic Macular Edema, Diabetic Retinopathy, VEGF, VTDR, Vision-Threatening, anti-VEGF, anti-vascular endothelial growth factor, diabetes, diabetic macular edema, patients, vision-threatening diabetic retinopathy, women
Author NameAffiliation
Elizabeth A LundeenNational Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention
David B ReinNORC at the University of Chicago
John S WittenbornNORC at the University of Chicago
Jinan B SaaddineNational Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention
Giuseppina ImperatoreNational Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention
Emily Y ChewDivision of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health
  • 1 - 6

Datasets